• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于网络的抗癌药物组合预测。

Network-based prediction of anti-cancer drug combinations.

作者信息

Jiang Jue, Wei Xuxu, Lu YuKang, Li Simin, Xu Xue

机构信息

School of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei, China.

Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.

出版信息

Front Pharmacol. 2024 Aug 15;15:1418902. doi: 10.3389/fphar.2024.1418902. eCollection 2024.

DOI:10.3389/fphar.2024.1418902
PMID:39211773
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11357946/
Abstract

Drug combinations have emerged as a promising therapeutic approach in cancer treatment, aimed at overcoming drug resistance and improving the efficacy of monotherapy regimens. However, identifying effective drug combinations has traditionally been time-consuming and often dependent on chance discoveries. Therefore, there is an urgent need to explore alternative strategies to support experimental research. In this study, we propose network-based prediction models to identify potential drug combinations for 11 types of cancer. Our approach involves extracting 55,299 associations from literature and constructing human protein interactomes for each cancer type. To predict drug combinations, we measure the proximity of drug-drug relationships within the network and employ a correlation clustering framework to detect functional communities. Finally, we identify 61,754 drug combinations. Furthermore, we analyze the network configurations specific to different cancer types and identify 30 key genes and 21 pathways. The performance of these models is subsequently assessed through assays, which exhibit a significant level of agreement. These findings represent a valuable contribution to the development of network-based drug combination design strategies, presenting potential solutions to overcome drug resistance and enhance cancer treatment outcomes.

摘要

药物联合已成为癌症治疗中一种很有前景的治疗方法,旨在克服耐药性并提高单一疗法方案的疗效。然而,传统上确定有效的药物联合一直很耗时,而且往往依赖于偶然发现。因此,迫切需要探索替代策略来支持实验研究。在本研究中,我们提出基于网络的预测模型,以识别11种癌症的潜在药物联合。我们的方法包括从文献中提取55299个关联,并为每种癌症类型构建人类蛋白质相互作用组。为了预测药物联合,我们测量网络内药物-药物关系的接近度,并采用相关聚类框架来检测功能群落。最后,我们识别出61754种药物联合。此外,我们分析了不同癌症类型特有的网络配置,并识别出30个关键基因和21条通路。随后通过实验评估这些模型的性能,结果显示出显著的一致性。这些发现为基于网络的药物联合设计策略的发展做出了宝贵贡献,为克服耐药性和提高癌症治疗效果提供了潜在解决方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa25/11357946/4c94a853ceb0/fphar-15-1418902-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa25/11357946/3217c2612098/fphar-15-1418902-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa25/11357946/df084b4cc14e/fphar-15-1418902-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa25/11357946/4c94a853ceb0/fphar-15-1418902-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa25/11357946/3217c2612098/fphar-15-1418902-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa25/11357946/df084b4cc14e/fphar-15-1418902-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa25/11357946/4c94a853ceb0/fphar-15-1418902-g003.jpg

相似文献

1
Network-based prediction of anti-cancer drug combinations.基于网络的抗癌药物组合预测。
Front Pharmacol. 2024 Aug 15;15:1418902. doi: 10.3389/fphar.2024.1418902. eCollection 2024.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Prediction of Synergistic Drug Combinations for Prostate Cancer by Transcriptomic and Network Characteristics.通过转录组学和网络特征预测前列腺癌的协同药物组合
Front Pharmacol. 2021 Apr 12;12:634097. doi: 10.3389/fphar.2021.634097. eCollection 2021.
4
Diffusion mapping of drug targets on disease signaling network elements reveals drug combination strategies.疾病信号网络元件上药物靶点的扩散映射揭示了药物联合策略。
Pac Symp Biocomput. 2018;23:92-103.
5
Deep graph embedding for prioritizing synergistic anticancer drug combinations.用于优先排序协同抗癌药物组合的深度图嵌入
Comput Struct Biotechnol J. 2020 Feb 15;18:427-438. doi: 10.1016/j.csbj.2020.02.006. eCollection 2020.
6
SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.SCNrank:基于网络的排序的谱聚类揭示潜在的药物靶点及其在胰腺导管腺癌中的应用。
BMC Med Genomics. 2020 Apr 3;13(Suppl 5):50. doi: 10.1186/s12920-020-0681-6.
7
A network-based trans-omics approach for predicting synergistic drug combinations.一种基于网络的跨组学方法用于预测协同药物组合。
Commun Med (Lond). 2024 Jul 29;4(1):154. doi: 10.1038/s43856-024-00571-2.
8
Predicting drug synergy using a network propagation inspired machine learning framework.利用网络传播启发的机器学习框架预测药物协同作用。
Brief Funct Genomics. 2024 Jul 19;23(4):429-440. doi: 10.1093/bfgp/elad056.
9
Prediction of Synergistic Antibiotic Combinations by Graph Learning.通过图学习预测协同抗生素组合
Front Pharmacol. 2022 Mar 8;13:849006. doi: 10.3389/fphar.2022.849006. eCollection 2022.
10
NEXGB: A Network Embedding Framework for Anticancer Drug Combination Prediction.NEXGB:一种用于抗癌药物组合预测的网络嵌入框架。
Int J Mol Sci. 2022 Aug 30;23(17):9838. doi: 10.3390/ijms23179838.

引用本文的文献

1
Synergistic anticancer effects of camptothecin and sotorasib in -mutated pancreatic ductal adenocarcinoma.喜树碱与索托拉西布对KRAS突变型胰腺导管腺癌的协同抗癌作用
Front Pharmacol. 2025 Jul 18;16:1635449. doi: 10.3389/fphar.2025.1635449. eCollection 2025.

本文引用的文献

1
Anti-cancer drug combinations approved by US FDA from 2011 to 2021: main design features of clinical trials and role of pharmacokinetics.2011 年至 2021 年美国 FDA 批准的抗癌药物联合治疗方案:临床试验的主要设计特点和药代动力学作用。
Cancer Chemother Pharmacol. 2022 Oct;90(4):285-299. doi: 10.1007/s00280-022-04467-7. Epub 2022 Aug 27.
2
Machine learning approaches for drug combination therapies.机器学习在药物联合疗法中的应用。
Brief Bioinform. 2021 Nov 5;22(6). doi: 10.1093/bib/bbab293.
3
MatchMaker: A Deep Learning Framework for Drug Synergy Prediction.
MatchMaker:一种用于药物协同作用预测的深度学习框架。
IEEE/ACM Trans Comput Biol Bioinform. 2022 Jul-Aug;19(4):2334-2344. doi: 10.1109/TCBB.2021.3086702. Epub 2022 Aug 8.
4
The European Lead Factory: An updated HTS compound library for innovative drug discovery.欧洲先导化合物工厂:用于创新药物发现的更新高通量筛选化合物库。
Drug Discov Today. 2021 Oct;26(10):2406-2413. doi: 10.1016/j.drudis.2021.04.019. Epub 2021 Apr 20.
5
Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects.利用多向相互作用系统地预测临床前药物组合效应。
Nat Commun. 2020 Dec 1;11(1):6136. doi: 10.1038/s41467-020-19950-z.
6
Artificial intelligence in drug discovery and development.人工智能在药物发现和开发中的应用。
Drug Discov Today. 2021 Jan;26(1):80-93. doi: 10.1016/j.drudis.2020.10.010. Epub 2020 Oct 21.
7
A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer.靶向谷氨酰胺成瘾的强效药物联合治疗策略用于人类肝癌的治疗。
Elife. 2020 Oct 5;9:e56749. doi: 10.7554/eLife.56749.
8
Synergistic Drug Combination Prediction by Integrating Multiomics Data in Deep Learning Models.基于深度学习模型整合多组学数据进行协同药物组合预测。
Methods Mol Biol. 2021;2194:223-238. doi: 10.1007/978-1-0716-0849-4_12.
9
Dihydroartemisinin Modulates Apoptosis and Autophagy in Multiple Myeloma through the P38/MAPK and Wnt/-Catenin Signaling Pathways.双氢青蒿素通过 P38/MAPK 和 Wnt/-Catenin 信号通路调节多发性骨髓瘤细胞的凋亡和自噬。
Oxid Med Cell Longev. 2020 Aug 15;2020:6096391. doi: 10.1155/2020/6096391. eCollection 2020.
10
High-Throughput Screening: today's biochemical and cell-based approaches.高通量筛选:今天的生化和基于细胞的方法。
Drug Discov Today. 2020 Oct;25(10):1807-1821. doi: 10.1016/j.drudis.2020.07.024. Epub 2020 Aug 12.